{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-120391","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2022-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.611115+00:00","generated_at":"2026-06-21T15:46:42.911421+00:00","sec_items":["1.01","1.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Iovance signs $500M at-the-market equity offering with Jefferies, replacing prior facility","bullets":["New Open Market Sale Agreement with Jefferies allows sale of up to $500M in common stock at the market.","Prior ATM agreement dated February 8, 2021 was terminated concurrent with the new agreement.","Jefferies will receive up to 3.0% commission on gross proceeds from any shares sold.","Sales are discretionary; the company is not obligated to sell any shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-120391","json":"https://secwatch.observer/filing/0001104659-22-120391.json","markdown":"https://secwatch.observer/filing/0001104659-22-120391.md","text":"https://secwatch.observer/filing/0001104659-22-120391.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465922120391/0001104659-22-120391-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465922120391/tm2230330d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T15:46:42.911421+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d6f69169061ae298cab857284dbadabf1b3088f","claim":"IOVANCE BIOTHERAPEUTICS, INC. terminated Prior Sales Agreement with Jefferies (effective 2022-11-18).","evidence_excerpt":"On November 18, 2022, the Company terminated its Open Market Sale Agreement, dated February 8, 2021, with Jefferies (the “Prior Sales Agreement”) related to the offer and sale of shares of the Company's common stock in at-the-market offerings.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465922120391/0001104659-22-120391-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Jefferies"},{"label":"Effective","value":"2022-11-18"}],"fact_type":"material_agreement"},{"claim_id":"c2a73664d641f89673c871ce4dd9875d596830cf","claim":"IOVANCE BIOTHERAPEUTICS, INC. entered into Sales Agreement with Jefferies LLC valued at $500.0 million (effective 2022-11-18).","evidence_excerpt":"On November 18, 2022, the Company entered into a new Open Market Sale Agreement (the “ Sales Agreement ”) with Jefferies LLC (“Jefferies”) with respect to an at the market offering program, under which the Company may, from time to time in its sole discretion, issue and sell through Jefferies, acting as sales agent, up to $500.0 million of shares of the Company's common stock, par value $0.000041666 per share (the “Common Shares”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465922120391/0001104659-22-120391-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Jefferies LLC"},{"label":"Value","value":"$500.0 million"},{"label":"Effective","value":"2022-11-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}